Pharmacoeconomic Studies:

With an increasingly elderly population the burden of health care costs continue to rise. Restricting costs and rationing the use of treatments is now a fact of life even within some privately funded healthcare companies.

Emergence of the fourth hurdle of cost-effectiveness data is now a regulatory requirement in many European and North American health care systems but unlike clinical trials there is no global standardisation.

Evicom undertake quality pharmacoeconomic studies which utilise information that can be readily adapted across different healthcare systems and cost structures.

Studies are also undertaken to underpin the development of pharmacoeconomic decision analysis models which are now highly recommended in reimbursement submissions.

We work closely with regulatory groups involved in the consideration of economic evidence across Belgium, Canada, Finland, France, Norway, Portugal, Italy, Spain, Sweden, UK and USA.

Quality and related biases in pharmacoeconomic evidence can reduce the chances of overcoming the fourth hurdle. Our studies aim to provide robust evidence that can withstand the highest level of scrutiny.

Evicom also advise on how best to tag economic studies onto clinical trials and provide a full pharmacoeconomic analysis service that can be customised on a country-specific or global basis.

Key types of studies performed are cost-effectiveness or cost-utility analysis dependent on the technology or guidance assessed.